Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, Department of Dermatology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Eur J Dermatol. 2023 Apr 1;33(2):87-100. doi: 10.1684/ejd.2023.4456.
Recently, dupilumab has been used for the treatment of atopic dermatitis (AD), and growing interest in the subject has resulted in an increasing number of publications.
Our study aimed to evaluate the rapid progress, identify hot topics, and explore scientific advances and future trends in this field.
MATERIALS & METHODS: The global distribution of publications was estimated with no time restrictions. Dupilumab as a treatment for AD was scanned in the Web of Science core collection using the topic terms "dupilumab" and "atopic Dermatitis". VOSviewer was applied for visualization of bibliometric analysis. Analysis of country and region distribution, impact of journal, authors, population, economic estimation among countries and regions, key words, as well as the top 20 cited articles were performed.
In total, 910 publications were yielded from the Web of Science core collection database. Most studies were published in the USA (46.15%), Germany (17.91%), and France (14.07%); other countries included Denmark, the Netherlands, and Canada based on normalization of article numbers according to population and economic evaluation. Studies were most frequently reported in the British Journal of Dermatology and the Journal of the American Academy of Dermatology. Pirozzi, G. from France was the top-cited author. The most frequent key words were concepts in dermatology, allergy, and immunology. Remarkable landmark clinical trials were noted in the top 20 cited publications.
The research of dupilumab for AD is rapidly developing. Countries in North America and Europe have remarkably contributed to researches of dupilumab as a treatment for AD. The bibliometric analysis also presents hallmark publications reporting scientific advances in therapy progress, which may provide a foundation for further research.
近年来，度普利尤单抗已被用于治疗特应性皮炎（AD），并且对该领域的兴趣日益浓厚，导致相关出版物数量不断增加。
我们的研究旨在评估该领域的快速发展，确定热点，探索该领域的科学进展和未来趋势。
本研究无时间限制地评估了全球出版物的分布情况。在 Web of Science 核心合集数据库中，使用主题词“dupilumab”和“atopic Dermatitis”对作为 AD 治疗方法的度普利尤单抗进行了扫描。VOSviewer 用于可视化文献计量分析。对国家和地区分布、期刊影响力、作者、人群、国家和地区经济评估、关键词以及前 20 名高被引文章进行了分析。
从 Web of Science 核心合集数据库中共获得 910 篇出版物。大多数研究来自美国（46.15%）、德国（17.91%）和法国（14.07%）；根据人口和经济评估对文章数量进行标准化后，其他国家还包括丹麦、荷兰和加拿大。研究最常发表在《英国皮肤病学杂志》和《美国皮肤病学会杂志》上。来自法国的皮罗齐（G.）是被引频次最高的作者。最常见的关键词是皮肤病学、过敏和免疫学的概念。前 20 名高被引文章中提到了一些重要的里程碑式临床试验。
AD 用度普利尤单抗的研究正在迅速发展。北美和欧洲国家在 AD 用度普利尤单抗研究方面做出了显著贡献。文献计量分析还展示了报告治疗进展科学进步的标志性出版物，可为进一步研究提供基础。
